Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show

Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show

311832

Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show

Orladeyo (berotralstat) reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) and improved their quality of life over the course of one year, according to the latest findings from the long-term APeX-S trial. The approved oral medication also was able to sustainably lower HAE attack rates and improve patients’ treatment satisfaction in those switching from injectable prophylactic (preventive) therapies to Orladeyo. Findings were presented at the 2021 Annual Scientific Meeting of the…

You must be logged in to read/download the full post.